Skip to main content
BioPorto logo

BioPorto — Investor Relations & Filings

Ticker · BIOPOR ISIN · DK0011048619 LEI · 5299004SWFL5JAN4W830 CO Manufacturing
Open in API
Filings indexed 788 across all filing types
Latest filing 2023-05-30 Share Issue/Capital Cha…
Country DK Denmark
Listing CO BIOPOR

About BioPorto

https://bioporto.com/

BioPorto is an in vitro diagnostics company specializing in actionable biomarkers to improve kidney health. The company's primary focus is the development and commercialization of diagnostic tests based on the Neutrophil Gelatinase-Associated Lipocalin (NGAL) biomarker for the early risk assessment and diagnosis of acute kidney injury (AKI). Its product portfolio includes The NGAL Test™ for clinical use and the FDA-cleared ProNephro AKI (NGAL) test for pediatric applications. These tools enable clinicians to detect kidney damage earlier than traditional methods, facilitating timely intervention. BioPorto also provides a range of NGAL ELISA kits and antibodies for preclinical and clinical research settings.

Recent filings

Filing Released Lang Actions
BioPorto A/S initiates a rights issue with pre-emptive rights for its existing shareholders and proceeds of up to approximately DKK 59.4 million with approximately DKK 16.6 million pre-subscribed purs
Share Issue/Capital Change Classification · 100% confidence The document is an official announcement from BioPorto A/S regarding a rights issue (capital raise) for existing shareholders. It details the number of shares, subscription price, pre-emptive rights, and the timeline for the offering. This falls squarely under the definition of a 'Share Issue/Capital Change' (SHA) as it describes the issuance of new shares and the mechanics of the capital increase.
2023-05-30 English
Share Issue/Capital Change 2023
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces an 'Increase in share capital following exercise of warrants' and details the resulting change in the total number of shares and voting rights, referencing the Danish Capital Markets Act. This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition for 'Share Issue/Capital Change' (Code: SHA). Although it mentions proceeds received in Q1 2023 (related to an Interim Report), the primary purpose of this specific announcement is the capital structure adjustment itself, not the periodic financial results.
2023-05-23 English
Increase in share capital following exercise of warrants – Notice of changes in share capital and voting rights pursuant to section 32 of the Danish Capital Markets Act
Share Issue/Capital Change Classification · 98% confidence The document is an official announcement regarding an increase in share capital due to the exercise of warrants. It explicitly mentions changes in share capital and voting rights pursuant to the Danish Capital Markets Act. This falls under the category of share issues or capital changes. While it mentions an attachment, the document itself provides the substantive details of the capital increase, making it a primary announcement rather than just a report publication notice.
2023-05-23 Danish
Annual Report 2022
Annual Report Classification · 95% confidence The document is titled 'BioPorto Annual Report 2022' and contains detailed sections typical of an annual report, including a letter to stakeholders, strategy, outlook, consolidated financial highlights, risk management, corporate governance, shareholder matters, board of directors, executive management, financial review, financial statements, notes to financial statements, statement by the board and management, and an independent auditor's report. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content includes comprehensive financial and operational information, strategic priorities, and detailed discussion of the company's products and market opportunities. This matches the definition of an Annual Report (10-K) which covers company activity and full financial performance for the year. Therefore, the correct classification is Annual Report (10-K) with high confidence. FY 2022
2023-03-30 English
Annual Report 2022
Annual Report Classification · 100% confidence The document is titled 'BioPorto Annual Report 2022' and contains a comprehensive table of contents covering financial highlights, risk management, corporate governance, financial statements, and an independent auditor's report. It is a full-length annual report detailing the company's performance, strategy, and financial position for the fiscal year 2022, fitting the definition of a 10-K (Annual Report). FY 2022
2023-03-30 English
BioPorto Announces Annual Results for the Year ended December 31, 2022
Remuneration Information Classification · 100% confidence The document is titled 'Remuneration Report 2022' for BioPorto A/S. It details the compensation, incentive programs, and shareholdings of the Board of Directors and Executive Management. This type of report is specifically mandated by corporate governance regulations (such as the Danish Companies Act mentioned in the text) to disclose executive and director pay. In the provided filing taxonomy, 'DEF 14A' is the designated category for Remuneration Information, as it covers compensation for top executives and directors.
2023-03-30 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.